摘要
The nanoparticle-based treatment and diagnosis of cancer remain challenging in clinical translation, mainly due to the hurdles that can be associated with the development of targeted delivery, biological side effects, poor drug loading efficiency (DLE), and instability and so on [1,2].
基金
supported by the National Key Research and Development Program of China (2017YFA0205201 and 2018YFA0107301)
the National Natural Science Foundation of China (81422023, U1705281, and U1505221)
the Fundamental Research Funds for the Central Universities (20720160065 and 20720150141)
the Program for New Century Excellent Talents in University, China (NCET-13-0502)
